AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18515521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinecatechins ointment 15%
Number of subjects: 502
Study 18515521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinecatechins ointment 10%
Number of subjects: 502
Study 18515521 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 502
Study 16548420 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken Essence (CE)
Number of subjects: 12
Study 16548420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11728498 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-closure of visceral peritoneum
Number of subjects: 100
Study 11728498 — intervention group
Group type: COMPARATOR
Intervention: Closure of visceral peritoneum
Number of subjects: 100
Study 9154289 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost eye drops
Number of subjects: 100
Study 7893988 — intervention group
Group type: EXPERIMENTAL
Intervention: poly(I)-poly(C12U)
Number of subjects: 0
Study 7893988 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 3312658 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole troches
Number of subjects: 60
Study 3312658 — intervention group
Group type: COMPARATOR
Intervention: Nystatin oral suspension
Number of subjects: 60
Study 29743534 — intervention group
Group type: EXPERIMENTAL
Intervention: Community detection algorithms (modularity maximisation, graph partitioning)
Number of subjects: 0
Study 29743534 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method
Number of subjects: 0
Study 29743534 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 26719035 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular concurrent exercise training for 30 weeks
Number of subjects: 38
Study 26719035 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 38
Study 23813320 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal contact
Number of subjects: 1032
Study 23813320 — intervention group
Group type: COMPARATOR
Intervention: Interactive technology
Number of subjects: 1032
Study 23813320 — intervention group
Group type: COMPARATOR
Intervention: Self‐directed
Number of subjects: 1032
Study 21740829 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 1159
Study 21740829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 1159
Study 21740829 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of telmisartan and ramipril
Number of subjects: 1159
Study 21740829 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1159
Study 19460078 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional right atrial appendage pacing
Number of subjects: 0
Study 19460078 — intervention group
Group type: EXPERIMENTAL
Intervention: Low atrial septal pacing
Number of subjects: 0
Study 19460078 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing
Number of subjects: 0
Study 19460078 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of different pacing sites and AF suppression pacing
Number of subjects: 0
Study 19460078 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16997840 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA CTrach (CT)
Number of subjects: 104
Study 16997840 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 104
Study 15568249 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy combined with supragingival and subgingival scaling therapy
Number of subjects: 0
Study 15568249 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric oxygen therapy
Number of subjects: 0
Study 15568249 — intervention group
Group type: COMPARATOR
Intervention: Supragingival and subgingival scaling therapy
Number of subjects: 0
Study 11157369 — intervention group
Group type: EXPERIMENTAL
Intervention: High dialysate calcium concentration (HDCa; 3.5 mEq/L)
Number of subjects: 28
Study 9401410 — intervention group
Group type: EXPERIMENTAL
Intervention: IgAN < 45
Number of subjects: 38
Study 9401410 — intervention group
Group type: EXPERIMENTAL
Intervention: IgAN > 45
Number of subjects: 38
Study 9401410 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 38
Study 9401410 — intervention group
Group type: EXPERIMENTAL
Intervention: IgAN < 45 and IgAN > 45
Number of subjects: 38
Study 8492688 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume resistance exercise (HVRE)
Number of subjects: 7
Study 8492688 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume resistance exercise (LVRE)
Number of subjects: 7
Study 8492688 — intervention group
Group type: COMPARATOR
Intervention: Control (C) [no exercise]
Number of subjects: 7
Study 2851958 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid suture (interrupted)
Number of subjects: 195
Study 2851958 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglyconate suture (continuous)
Number of subjects: 195
Study 2851958 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene suture (continuous)
Number of subjects: 195
Study 29547978 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication ON
Number of subjects: 30
Study 29547978 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication OFF
Number of subjects: 30
Study 29547978 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 28383533 — intervention group
Group type: EXPERIMENTAL
Intervention: One capsule of daily iron supplement (34 mg of ferrous sulfate)
Number of subjects: 324
Study 28383533 — intervention group
Group type: COMPARATOR
Intervention: Two capsules of daily iron supplement (34 mg of ferrous sulfate)
Number of subjects: 324
Study 26488676 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose mirtazapine
Number of subjects: 0
Study 24200934 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella supplementation (8 g Chlorella/day/person; equivalent to 22.9 mg lutein/day/person)
Number of subjects: 12
Study 24200934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21362764 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg subcutaneously every 2 weeks for 52 weeks
Number of subjects: 0
Study 21362764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18682188 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐S saphenectomy with distal sclerosis
Number of subjects: 105
Study 18682188 — intervention group
Group type: COMPARATOR
Intervention: 3‐S saphenectomy
Number of subjects: 105
Study 21324452 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized aerobic exercise training for 16 weeks
Number of subjects: 8
Study 16021664 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset recurrent depression
Number of subjects: 181
Study 16021664 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset single-episode depression
Number of subjects: 181
Study 16021664 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset recurrent depression
Number of subjects: 181
Study 12422941 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 12422941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9690695 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone 160 mg/day
Number of subjects: 90
Study 9690695 — intervention group
Group type: COMPARATOR
Intervention: haloperidol 15 mg/day
Number of subjects: 90
Study 9690695 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone 4 mg/day
Number of subjects: 90
Study 9690695 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone 10 mg/day
Number of subjects: 90
Study 9690695 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone 40 mg/day
Number of subjects: 90
Study 9690695 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 90
Study 9690695 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone 160 mg/day and haloperidol 15 mg/day
Number of subjects: 90
Study 8081430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (30mg)
Number of subjects: 48
Study 8081430 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pI)
Number of subjects: 48
Study 2568105 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 2 sympathomimetic drugs administered by aerosol inhaler
Number of subjects: 100
Study 2568105 — intervention group
Group type: COMPARATOR
Intervention: Slow-release theophylline
Number of subjects: 100
Study 29514693 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 10^6/kg human umbilical-cord-derived MSCs (UC-MSCs) via peripheral vein before transplantation and 5 × 10^6 cells via renal artery during surgery
Number of subjects: 42
Study 29514693 — intervention group
Group type: COMPARATOR
Intervention: Standard induction therapy (non-MSC treatment)
Number of subjects: 42
Study 28246891 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (anode F3 and cathode F4, 2 mA intensity, 30 min/day)
Number of subjects: 152
Study 28246891 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 152
Study 25651922 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 9324
Study 23508603 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) point-of-care testing
Number of subjects: 379
Study 23508603 — intervention group
Group type: COMPARATOR
Intervention: No CRP point-of-care testing (Control)
Number of subjects: 379
Study 23508603 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training
Number of subjects: 379
Study 23508603 — intervention group
Group type: COMPARATOR
Intervention: No communication skills training (Control)
Number of subjects: 379
Study 21439529 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ezetimibe 10 mg/day and atorvastatin 40 mg/day
Number of subjects: 100
Study 21439529 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day and placebo (monotherapy group)
Number of subjects: 100
Study 18974446 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise interventions for prevention of falls and sarcopenia
Number of subjects: 0
Study 18974446 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin D concentration
Number of subjects: 0
Study 17138156 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 50 ng/kg per minute under sedation with propofol (4 mg/kg per hour)
Number of subjects: 9
Study 17138156 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 50 ng/kg per minute under sedation with midazolam (0.2 mg/kg per hour)
Number of subjects: 9
Study 17138156 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 50 ng/kg per minute under sedation with nitrous oxide (30% inhalation)
Number of subjects: 9
Study 14562489 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based, nurse-facilitated support group (met twice weekly for 4 weeks)
Number of subjects: 65
Study 14562489 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 65
Study 10781117 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled propofol sedation
Number of subjects: 18
Study 10781117 — intervention group
Group type: COMPARATOR
Intervention: Clinician-controlled propofol sedation
Number of subjects: 18
Study 8776195 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental design approach using a combination of solution concentration, air exchange rate, and body type in a cross-classified design for estimating historical exposures to formaldehyde.
Number of subjects: 25
Study 8776195 — intervention group
Group type: COMPARATOR
Intervention: Statistical models based on available exposure data.
Number of subjects: 25
Study 1731596 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 679
Study 1731596 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin for 12 wk (R3)
Number of subjects: 679
Study 1731596 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid and rifampin for 12 wk (HR3)
Number of subjects: 679
Study 1731596 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid alone for 24 wk (H6)
Number of subjects: 679
Study 6150888 — intervention group
Group type: EXPERIMENTAL
Intervention: SST-14 (3.5 microgram kg‐1 h‐1)
Number of subjects: 10
Study 6150888 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201-995 (0.14, 0.28, 0.56, or 1.12 microgram kg‐1 h‐1)
Number of subjects: 10
Study 31842674 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous antegrade flexible intramedullary nailing (Group I)
Number of subjects: 46
Study 31842674 — intervention group
Group type: COMPARATOR
Intervention: Crossed Kirschner-wires (Group II)
Number of subjects: 46
Study 28960486 — intervention group
Group type: EXPERIMENTAL
Intervention: GP2015 (etanercept biosimilar)
Number of subjects: 531
Study 28960486 — intervention group
Group type: COMPARATOR
Intervention: ETN (Enbrel®)
Number of subjects: 531
Study 27297245 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy (DC)
Number of subjects: 213
Study 27297245 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment only
Number of subjects: 213
Study 25035783 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical FESS (RFESS)
Number of subjects: 60
Study 25035783 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative FESS (CFESS)
Number of subjects: 60
Study 23512415 — intervention group
Group type: COMPARATOR
Intervention: Regular Human Insulin (RHI)
Number of subjects: 29
Study 23512415 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IA)
Number of subjects: 29
Study 19838618 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk fermented by S. thermophilus and Lactobacillus casei, with Lactobacillus acidophilus, oligofructose and inulin added after fermentation (test product)
Number of subjects: 162
Study 19838618 — intervention group
Group type: COMPARATOR
Intervention: Low-fat milk fermented by S. thermophilus (control product)
Number of subjects: 162
Study 18380741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitz bath (twice-daily) along with antibiotics and analgesics
Number of subjects: 50
Study 18380741 — intervention group
Group type: COMPARATOR
Intervention: Control (antibiotics and analgesics alone)
Number of subjects: 50
Study 16618974 — intervention group
Group type: EXPERIMENTAL
Intervention: cookie test
Number of subjects: 64
Study 16618974 — intervention group
Group type: COMPARATOR
Intervention: liquid glucose
Number of subjects: 64
Study 15375790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg)
Number of subjects: 27
Study 15375790 — intervention group
Group type: COMPARATOR
Intervention: Glyburide (10 mg)
Number of subjects: 27
Study 11352951 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg once daily
Number of subjects: 907
Study 11352951 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg once daily
Number of subjects: 907
Study 9221851 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior resection (LAR)
Number of subjects: 40
Study 9221851 — intervention group
Group type: COMPARATOR
Intervention: Open anterior resection (OAR)
Number of subjects: 40
Study 8244838 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced key press with attention on movement (Part 1)
Number of subjects: 16
Study 8244838 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination of two tones triggered by key press (Part 2)
Number of subjects: 16
Study 8244838 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-movement potential after negative RP
Number of subjects: 16
Study 8244838 — intervention group
Group type: EXPERIMENTAL
Intervention: N100 response to tone after positive RPs
Number of subjects: 16
Study 3629205 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-laser therapy (He-Ne laser, 6 J/cm2, 9 treatments)
Number of subjects: 17
Study 3629205 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation (control group)
Number of subjects: 17
Study 29289583 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus standing balance circuit classes (1-hour class, 3 times a week for 2 weeks)
Number of subjects: 162
Study 29289583 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy alone
Number of subjects: 162
Study 27662442 — intervention group
Group type: EXPERIMENTAL
Intervention: Health communication intervention (specifics not provided)
Number of subjects: 410
Study 25632085 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (mean exposure to study drug, 2.4 years)
Number of subjects: 3635
Study 21396848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (5 g 2.5%) 20 minutes before TPB
Number of subjects: 300
Study 21396848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-ketorolac gel (5 g 2.5% lidocaine + 0.3% ketorolac tromethamine) 1 hour before TPB
Number of subjects: 300
Study 21396848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel (5 g 2.5%) 10 minutes before TPB
Number of subjects: 300
Study 20872196 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy + resection + adjuvant therapy with imatinib
Number of subjects: 41
Study 20872196 — intervention group
Group type: COMPARATOR
Intervention: Imatinib alone
Number of subjects: 41
Study 18212624 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided HALDN
Number of subjects: 60
Study 18212624 — intervention group
Group type: COMPARATOR
Intervention: Right-sided HALDN
Number of subjects: 60
Study 17022854 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paracetamol 1 g
Number of subjects: 40
Study 17022854 — intervention group
Group type: COMPARATOR
Intervention: IV dipyrone 1 g
Number of subjects: 40
Study 15053490 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy for 20 minutes twice per week over the course of one month
Number of subjects: 30
Study 15053490 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 30
Study 10049409 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal route with 6.0 mm diameter pediatric videoendoscope
Number of subjects: 100
Study 10049409 — intervention group
Group type: COMPARATOR
Intervention: Oral route with 6.0 mm diameter standard videoendoscope
Number of subjects: 100
Study 10049409 — intervention group
Group type: COMPARATOR
Intervention: Oral route with 6.0 mm diameter pediatric videoendoscope
Number of subjects: 100
Study 7783058 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA) group
Number of subjects: 20
Study 7783058 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 20
Study 2169784 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg; n = 114) administered as a 5 min infusion, with two additional 40 micrograms/kg doses allowed
Number of subjects: 234
Study 2169784 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide plus dexamethasone (120 patients) - Dexamethasone 12 mg intravenously over 30 min, followed by a loading dose of 3 mg/kg metoclopramide, then maintenance dose of 4 mg/kg over 8 h
Number of subjects: 234
Study 6991106 — intervention group
Group type: EXPERIMENTAL
Intervention: methyl‐CCNU‐cyclophosphamide‐prednisone (group A)
Number of subjects: 139
Study 6991106 — intervention group
Group type: COMPARATOR
Intervention: melphalan‐prednisone (group B)
Number of subjects: 139
Study 6991106 — intervention group
Group type: EXPERIMENTAL
Intervention: good response patients
Number of subjects: 139
Study 6991106 — intervention group
Group type: EXPERIMENTAL
Intervention: partial response patients
Number of subjects: 139
Study 6991106 — intervention group
Group type: EXPERIMENTAL
Intervention: no response patients
Number of subjects: 139
Study 6991106 — intervention group
Group type: EXPERIMENTAL
Intervention: stage I patients
Number of subjects: 139
Study 6991106 — intervention group
Group type: EXPERIMENTAL
Intervention: stage II patients
Number of subjects: 139
Study 6991106 — intervention group
Group type: EXPERIMENTAL
Intervention: stage III patients
Number of subjects: 139
Study 31983056 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (300 or 150 mg)
Number of subjects: 858
Study 31983056 — intervention group
Group type: COMPARATOR
Intervention: SDZ-ADL (40 mg)
Number of subjects: 858
Study 29973755 — intervention group
Group type: EXPERIMENTAL
Intervention: Popsicle
Number of subjects: 109
Study 29973755 — intervention group
Group type: EXPERIMENTAL
Intervention: Popsicle (whole vs partially eaten)
Number of subjects: 109
Study 29973755 — intervention group
Group type: COMPARATOR
Intervention: Control (no popsicle)
Number of subjects: 109
Study 27835037 — intervention group
Group type: EXPERIMENTAL
Intervention: Android‐HCLS
Number of subjects: 28
Study 27835037 — intervention group
Group type: COMPARATOR
Intervention: SAP‐LGS
Number of subjects: 28
Study 24604234 — intervention group
Group type: EXPERIMENTAL
Intervention: PGL2001 (E2MATE) at 4 mg/week
Number of subjects: 24
Study 24604234 — intervention group
Group type: EXPERIMENTAL
Intervention: PGL2001 (E2MATE) + NETA
Number of subjects: 24
Study 23496302 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump therapy
Number of subjects: 481
Study 23496302 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections + self monitoring of blood glucose
Number of subjects: 481
Study 21322181 — intervention group
Group type: EXPERIMENTAL
Intervention: sirdalud MR (tizanidine modified release) 6 mg per day
Number of subjects: 54
Study 21322181 — intervention group
Group type: COMPARATOR
Intervention: sirdalud (standard form of tizanidine) 2 mg 3 times daily
Number of subjects: 54
Study 18504443 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated exercise (ten 3‐min bouts of cycling at 60% of maximum heart rate)
Number of subjects: 8
Study 18504443 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise (one 30‐min bout of cycling at 60% of maximum heart rate)
Number of subjects: 8
Study 18504443 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 8
Study 16637392 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization surgery
Number of subjects: 20
Study 16637392 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control)
Number of subjects: 20
Study 14695409 — intervention group
Group type: COMPARATOR
Intervention: Single autologous stem-cell transplantation
Number of subjects: 399